0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Triazenes - Chemical, Biological, and Clinical Aspects (Paperback, Softcover reprint of the original 1st ed. 1990) Loot Price: R1,401
Discovery Miles 14 010
Triazenes - Chemical, Biological, and Clinical Aspects (Paperback, Softcover reprint of the original 1st ed. 1990): Tullio...

Triazenes - Chemical, Biological, and Clinical Aspects (Paperback, Softcover reprint of the original 1st ed. 1990)

Tullio Giraldi, Thomas Connors, Giuseppe Cartei

 (sign in to rate)
Loot Price R1,401 Discovery Miles 14 010 | Repayment Terms: R131 pm x 12*

Bookmark and Share

Expected to ship within 18 - 22 working days

More than 25 years have elapsed since the development of the seminal idea which led to the synthesis of dimethyl triazenes as antitumor agents. The original suggestion of Shealy et ale was to use 4-imidazone-carboxarnide as the carrier of a nitro- gen-containing cytotoxic function. 5-diazoimidazole-4-carbox- amide (diazo-IC) was synthesized and tested in mice as a potential inhibitor of de novo purine biosynthesis. Its lack of antitumor action was attributed to its polarity and to the resulting poor uptake of this hydrophilic chemical. Diazo-IC was then coupled with dimethylamine, yielding 5, (3,3-dimethyl- l-triazeno)imidazole-4-carboxamide) (DTIC) with the intention of obtaining a less polar and more lipophil~c prod rug which might release diazo-IC intracellularly. Preliminary tests showed that DTIC had good antiumor activity in experimental systems. Further tests demonstrated a broad spectrum of action against rodent tumors, and clinical trials indicated activity against human malignancies. Subsequent clinical use of DTIC has demonstrated its usefulness against malignant melanoma, for which it is currently the drug of choice, and its effective- ness in combination chemotherapy in the treatment of other human cancers. Because of its antitumor activity the mechan- ism of action of DTIC has been investigated in some detail. The original rationale for its development, that is, the hydrolysis in vivo to diazo-IC, has been shown not to be in- volved in th-e-mechansims of action. DTIC requires metabolic acti- vation before it exerts its biological effects.

General

Imprint: Springer-Verlag New York
Country of origin: United States
Release date: March 2013
First published: 1990
Editors: Tullio Giraldi • Thomas Connors • Giuseppe Cartei
Dimensions: 244 x 170 x 12mm (L x W x T)
Format: Paperback
Pages: 227
Edition: Softcover reprint of the original 1st ed. 1990
ISBN-13: 978-1-4613-6710-9
Categories: Books > Science & Mathematics > Biology, life sciences > Biochemistry > General
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Promotions
LSN: 1-4613-6710-7
Barcode: 9781461367109

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners